Kamada (KMDA) FCF Margin (2012 - 2026)
Kamada's (KMDA) quarterly FCF Margin came in at 36.73% in Q2 2026, up 1431.0% on a YoY basis from 2.4% in Q2 2025, and up 2336.76% quarter-over-quarter from 1.51% in Q1 2026.
Analysis
Kamada (KMDA) FCF Margin (2012 - 2026) Analysis & Trends
Kamada (KMDA) has reported FCF Margin for 15 consecutive years, with 36.73% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, FCF Margin rose 1431.0% year-over-year to 36.73%; the trailing twelve-month figure through Jun 2026 stood at 23.56% (down 514.0% YoY), and the FY2025 full-year result was 19.58%, down 1666.0% from the prior year.
- FCF Margin improved to 36.73% in Q2 2026 per KMDA's latest filing, from 1.51% in the prior quarter.
- Across five years, FCF Margin topped out at 58.31% in Q3 2024 and bottomed at 5.65% in Q1 2023.
- Historically, FCF Margin has averaged 22.14% across 5 years, with a median of 22.13% in 2022.
- The sharpest annual moves came in 2022 and 2023: FCF Margin surged 5706 bps in 2022, then slumped 4142 bps in 2023.
- Over 5 years, FCF Margin stood at 16.99% in 2022, then soared by 31 bps to 22.19% in 2023, then jumped by 54 bps to 34.15% in 2024, then sank by 32 bps to 23.15% in 2025, then surged by 59 bps to 36.73% in 2026.
- According to Business Quant data, FCF Margin over the past three periods registered 36.73%, 1.51%, and 23.15% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.30 Bn | 197.31 Bn | 7.24 Bn | 34.70% |
| 2 | Gilead Sciences | 180.97 Bn | 177.79 Bn | 6.22 Bn | 44.00% |
| 3 | Vertex Pharmaceuticals | 132.27 Bn | 124.42 Bn | 2.84 Bn | 30.39% |
| 4 | Regeneron Pharmaceuticals | 82.93 Bn | 74.93 Bn | 3.93 Bn | 13.35% |
| 5 | Argenx Se | 61.53 Bn | 56.35 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.27 Bn | 49.13 Bn | 52.00 Mn | -388.28% |
| 7 | Alnylam Pharmaceuticals | 34.46 Bn | 31.15 Bn | 992.69 Mn | 22.62% |
| 8 | Biogen | 31.16 Bn | 29.88 Bn | 1.96 Bn | 14.91% |
| 9 | Roivant Sciences | 30.08 Bn | 30.08 Bn | 1.16 Mn | -18,629.40% |
| 10 | Kamada | 473.85 Mn | 403.72 Mn | 22.47 Mn | 36.73% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 36.73% |
| Mar 31, 2026 | 1.51% |
| Dec 31, 2025 | 23.15% |
| Sep 30, 2025 | 29.79% |
| Jun 30, 2025 | 22.42% |
| Mar 31, 2025 | 2.17% |
| Dec 31, 2024 | 34.15% |
| Sep 30, 2024 | 58.31% |
| Jun 30, 2024 | 39.96% |
| Mar 31, 2024 | 9.81% |
| Dec 31, 2023 | 22.19% |
| Sep 30, 2023 | 6.99% |
| Jun 30, 2023 | 7.61% |
| Mar 31, 2023 | -5.65% |
| Dec 31, 2022 | 16.99% |
| Sep 30, 2022 | 22.06% |
| Jun 30, 2022 | 49.03% |
| Mar 31, 2022 | 21.28% |
| Dec 31, 2021 | -13.43% |
| Sep 30, 2021 | -4.99% |